Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants

Yasuhiro Koga, Shoji Tokunaga, Jun Nagano, Fuyuhiko Sato, Kenta Konishi, Takumi Tochio, Youko Murakami, Natsuko Masumoto, Jun Ichirou Tezuka, Nobuyuki Sudo, Chiharu Kubo, Rumiko Shibata

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Although Faecalibacterium prausnitzii is a major bacterium in the intestine of adults, which is known to have anti-inflammatory effects, the development in infants or the response to prebiotics remains unclear.Methods:The counts of F. prausnitzii in the feces were examined by real-time polymerase chain reaction (PCR). Fecal samples were obtained from 65 atopic dermatitis (AD) infants who participated in a randomized controlled clinical trial to investigate the therapeutic effect of kestose, the smallest fructooligosaccharide.Results:Although the F. prausnitzii count was undetectable level in most 0- to 1-y-old infants, the count reached a level comparable to that in adults in 2- to 5-y-old infants. The bacterial number increased about 10-fold by oral administration of kestose every day for 12 wk in the younger infants, but not so much in the older infants. This bacterial increase was significantly correlated with an improvement in the AD symptoms in the older infants.Conclusion:The F. prausnitzii population in the intestine reaches a level comparable to that in adult at approximately 2 y of age. Kestose efficiently stimulates the growth of this bacterium in the intestine, which might lead to an improvement in AD symptoms in infants.

Original languageEnglish
Pages (from-to)844-851
Number of pages8
JournalPediatric Research
Volume80
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Atopic Dermatitis
Intestines
Bacteria
Prebiotics
Therapeutic Uses
Child Development
Faecalibacterium prausnitzii
Feces
Oral Administration
Real-Time Polymerase Chain Reaction
Anti-Inflammatory Agents
Randomized Controlled Trials
Growth
Population

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants. / Koga, Yasuhiro; Tokunaga, Shoji; Nagano, Jun; Sato, Fuyuhiko; Konishi, Kenta; Tochio, Takumi; Murakami, Youko; Masumoto, Natsuko; Tezuka, Jun Ichirou; Sudo, Nobuyuki; Kubo, Chiharu; Shibata, Rumiko.

In: Pediatric Research, Vol. 80, No. 6, 01.12.2016, p. 844-851.

Research output: Contribution to journalArticle

Koga, Y, Tokunaga, S, Nagano, J, Sato, F, Konishi, K, Tochio, T, Murakami, Y, Masumoto, N, Tezuka, JI, Sudo, N, Kubo, C & Shibata, R 2016, 'Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants', Pediatric Research, vol. 80, no. 6, pp. 844-851. https://doi.org/10.1038/pr.2016.167
Koga, Yasuhiro ; Tokunaga, Shoji ; Nagano, Jun ; Sato, Fuyuhiko ; Konishi, Kenta ; Tochio, Takumi ; Murakami, Youko ; Masumoto, Natsuko ; Tezuka, Jun Ichirou ; Sudo, Nobuyuki ; Kubo, Chiharu ; Shibata, Rumiko. / Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants. In: Pediatric Research. 2016 ; Vol. 80, No. 6. pp. 844-851.
@article{1f13373c61874218b5af30c125b9e4a8,
title = "Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants",
abstract = "Background: Although Faecalibacterium prausnitzii is a major bacterium in the intestine of adults, which is known to have anti-inflammatory effects, the development in infants or the response to prebiotics remains unclear.Methods:The counts of F. prausnitzii in the feces were examined by real-time polymerase chain reaction (PCR). Fecal samples were obtained from 65 atopic dermatitis (AD) infants who participated in a randomized controlled clinical trial to investigate the therapeutic effect of kestose, the smallest fructooligosaccharide.Results:Although the F. prausnitzii count was undetectable level in most 0- to 1-y-old infants, the count reached a level comparable to that in adults in 2- to 5-y-old infants. The bacterial number increased about 10-fold by oral administration of kestose every day for 12 wk in the younger infants, but not so much in the older infants. This bacterial increase was significantly correlated with an improvement in the AD symptoms in the older infants.Conclusion:The F. prausnitzii population in the intestine reaches a level comparable to that in adult at approximately 2 y of age. Kestose efficiently stimulates the growth of this bacterium in the intestine, which might lead to an improvement in AD symptoms in infants.",
author = "Yasuhiro Koga and Shoji Tokunaga and Jun Nagano and Fuyuhiko Sato and Kenta Konishi and Takumi Tochio and Youko Murakami and Natsuko Masumoto and Tezuka, {Jun Ichirou} and Nobuyuki Sudo and Chiharu Kubo and Rumiko Shibata",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/pr.2016.167",
language = "English",
volume = "80",
pages = "844--851",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants

AU - Koga, Yasuhiro

AU - Tokunaga, Shoji

AU - Nagano, Jun

AU - Sato, Fuyuhiko

AU - Konishi, Kenta

AU - Tochio, Takumi

AU - Murakami, Youko

AU - Masumoto, Natsuko

AU - Tezuka, Jun Ichirou

AU - Sudo, Nobuyuki

AU - Kubo, Chiharu

AU - Shibata, Rumiko

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Although Faecalibacterium prausnitzii is a major bacterium in the intestine of adults, which is known to have anti-inflammatory effects, the development in infants or the response to prebiotics remains unclear.Methods:The counts of F. prausnitzii in the feces were examined by real-time polymerase chain reaction (PCR). Fecal samples were obtained from 65 atopic dermatitis (AD) infants who participated in a randomized controlled clinical trial to investigate the therapeutic effect of kestose, the smallest fructooligosaccharide.Results:Although the F. prausnitzii count was undetectable level in most 0- to 1-y-old infants, the count reached a level comparable to that in adults in 2- to 5-y-old infants. The bacterial number increased about 10-fold by oral administration of kestose every day for 12 wk in the younger infants, but not so much in the older infants. This bacterial increase was significantly correlated with an improvement in the AD symptoms in the older infants.Conclusion:The F. prausnitzii population in the intestine reaches a level comparable to that in adult at approximately 2 y of age. Kestose efficiently stimulates the growth of this bacterium in the intestine, which might lead to an improvement in AD symptoms in infants.

AB - Background: Although Faecalibacterium prausnitzii is a major bacterium in the intestine of adults, which is known to have anti-inflammatory effects, the development in infants or the response to prebiotics remains unclear.Methods:The counts of F. prausnitzii in the feces were examined by real-time polymerase chain reaction (PCR). Fecal samples were obtained from 65 atopic dermatitis (AD) infants who participated in a randomized controlled clinical trial to investigate the therapeutic effect of kestose, the smallest fructooligosaccharide.Results:Although the F. prausnitzii count was undetectable level in most 0- to 1-y-old infants, the count reached a level comparable to that in adults in 2- to 5-y-old infants. The bacterial number increased about 10-fold by oral administration of kestose every day for 12 wk in the younger infants, but not so much in the older infants. This bacterial increase was significantly correlated with an improvement in the AD symptoms in the older infants.Conclusion:The F. prausnitzii population in the intestine reaches a level comparable to that in adult at approximately 2 y of age. Kestose efficiently stimulates the growth of this bacterium in the intestine, which might lead to an improvement in AD symptoms in infants.

UR - http://www.scopus.com/inward/record.url?scp=84995603682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995603682&partnerID=8YFLogxK

U2 - 10.1038/pr.2016.167

DO - 10.1038/pr.2016.167

M3 - Article

C2 - 27537603

AN - SCOPUS:84995603682

VL - 80

SP - 844

EP - 851

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -